The short form of dopamine D2 receptor (D2S) functions as a presynaptic autoreceptor on dopamine neurons and has an inhibitory effect on dopaminergic tone. D2-MAPKs pathway is involved in many physiological events like production of prolactin and tyrosine hydroxylase (TH) expression. However, the effect of D2S receptor signalling on MAPKs is cell type specific, and is not fully understood.A recent study in our lab has identified a Gαi-interacting ras-MAPK inhibitor RASA3. Here, we showed that RASA3 is the key effector in D2-induced inhibition of MAPK by knockdown of endogenous RASA3 in the GH4 cell using RASA3 siRNA. We have also transfected a dominant negative RASA3 to compete with the endogenous RASA3 for the binding site on Ras. Both RASA3-siRNA and dominant negative RASA3 blocked D2S-induced inhibition of MAPK activation, clearly implicating that RASA3 is a key effector in Gαi3-dependent D2S mediated MAPKs inhibition To determine whether RASA3’s inhibitory effect could be reconstituted in fibroblast cells, the effect of RASA3 on D2-mediated ERK1/2 activation in COS7 cells was tested. Our results show that both active Gαi2 (or Gαi3) and active RASA3 are required for optimal inhibition of ERK1/2 activation in fibroblast COS7 cells.

The short form of dopamine D2 receptor (D2S) functions as a presynaptic autoreceptor on dopamine neurons and has an inhibitory effect on dopaminergic tone. D2-MAPKs pathway is involved in many physiological events like production of prolactin and tyrosine hydroxylase (TH) expression. However, the effect of D2S receptor signalling on MAPKs is cell type specific, and is not fully understood.A recent study in our lab has identified a Gαi-interacting ras-MAPK inhibitor RASA3. Here, we showed that RASA3 is the key effector in D2-induced inhibition of MAPK by knockdown of endogenous RASA3 in the GH4 cell using RASA3 siRNA. We have also transfected a dominant negative RASA3 to compete with the endogenous RASA3 for the binding site on Ras. Both RASA3-siRNA and dominant negative RASA3 blocked D2S-induced inhibition of MAPK activation, clearly implicating that RASA3 is a key effector in Gαi3-dependent D2S mediated MAPKs inhibition To determine whether RASA3’s inhibitory effect could be reconstituted in fibroblast cells, the effect of RASA3 on D2-mediated ERK1/2 activation in COS7 cells was tested. Our results show that both active Gαi2 (or Gαi3) and active RASA3 are required for optimal inhibition of ERK1/2 activation in fibroblast COS7 cells.

The short form of dopamine D2 receptor (D2S) functions as a presynaptic autoreceptor on dopamine neurons and has an inhibitory effect on dopaminergic tone. D2-MAPKs pathway is involved in many physiological events like production of prolactin and tyrosine hydroxylase (TH) expression. However, the effect of D2S receptor signalling on MAPKs is cell type specific, and is not fully understood.A recent study in our lab has identified a Gαi-interacting ras-MAPK inhibitor RASA3. Here, we showed that RASA3 is the key effector in D2-induced inhibition of MAPK by knockdown of endogenous RASA3 in the GH4 cell using RASA3 siRNA. We have also transfected a dominant negative RASA3 to compete with the endogenous RASA3 for the binding site on Ras. Both RASA3-siRNA and dominant negative RASA3 blocked D2S-induced inhibition of MAPK activation, clearly implicating that RASA3 is a key effector in Gαi3-dependent D2S mediated MAPKs inhibition To determine whether RASA3’s inhibitory effect could be reconstituted in fibroblast cells, the effect of RASA3 on D2-mediated ERK1/2 activation in COS7 cells was tested. Our results show that both active Gαi2 (or Gαi3) and active RASA3 are required for optimal inhibition of ERK1/2 activation in fibroblast COS7 cells.

The short form of dopamine D2 receptor (D2S) functions as a presynaptic autoreceptor on dopamine neurons and has an inhibitory effect on dopaminergic tone. D2-MAPKs pathway is involved in many physiological events like production of prolactin and tyrosine hydroxylase (TH) expression. However, the effect of D2S receptor signalling on MAPKs is cell type specific, and is not fully understood.A recent study in our lab has identified a Gαi-interacting ras-MAPK inhibitor RASA3. Here, we showed that RASA3 is the key effector in D2-induced inhibition of MAPK by knockdown of endogenous RASA3 in the GH4 cell using RASA3 siRNA. We have also transfected a dominant negative RASA3 to compete with the endogenous RASA3 for the binding site on Ras. Both RASA3-siRNA and dominant negative RASA3 blocked D2S-induced inhibition of MAPK activation, clearly implicating that RASA3 is a key effector in Gαi3-dependent D2S mediated MAPKs inhibition To determine whether RASA3’s inhibitory effect could be reconstituted in fibroblast cells, the effect of RASA3 on D2-mediated ERK1/2 activation in COS7 cells was tested. Our results show that both active Gαi2 (or Gαi3) and active RASA3 are required for optimal inhibition of ERK1/2 activation in fibroblast COS7 cells.

RASA3 (Ras p21 GTPase Activating Protein 3) is required for D2SR (Dopamine D2 Short Receptor) induced ERK1/2 inhibition in pituitary lactotroph GH4ZR7 cells. We hypothesized that RASA3 may be important for D2SR signaling to inhibit ERK1/2 in dopamine neurons, and thus negatively regulate TH (Tyrosine Hydroxylase) expression and activity. We designed and made shRASA3 lentivirus and showed that it inhibits RASA3 expression. Lentivirus mediated RASA3 knockdown can partially reverse the D2SR mediated ERK1/2 inactivation in GH4ZR7 cells. We then showed that knockdown of RASA3 in dopamine-secreting PC12 cells increased NGF-stimulated ERK1/2 in cells expressing D2SR, but not in cells lacking D2SR, thus implicating RASA3 plays a role in D2SR-mediated inhibition of ERK1/2 signaling. We also found that knockdown of RASA3 increased TH protein levels in cells expressing D2R receptors but not those without D2SR, suggesting that D2SR tonically inhibits the synthesis of TH. We also found preliminary indication that mutant RASA3 mice show increased level of TH in SN compared to WT mice. RASA3 mutant mice showed no striking changes in basal locomotion, anxiety or depression phenotypes, but further studies are needed to specifically address dopamine-driven behaviors. In summary, our data support the role of RASA3 in mediating D2SR-induced inhibition of ERK1/2 in dopamine neurons to negatively regulate TH expression and activity.

Rasa3 est un membre de la famille GAP1 des GTPase activating proteins. Cette protéine stimule la fonction GTPase intrinsèque des petites protéines G telles que Ras et Rap. Rasa3 présente une haute affinité pour l’Ins(1,3,4,5)P4 et le PtdIns(4,5)P2, et est principalement exprimée dans les cellules du système hématopoïétique chez la souris.<p>Dans le but d’étudier chez la souris le rôle physiologique de Rasa3 dans les cellules hématopoïétiques, nous avons d’une part généré et analysé des souris transgéniques surexprimant une forme normale (TgN) ou mutée et catalytiquement inactive (TgM) de la protéine Rasa3 dans les lymphocytes B et/ou T. D’autre part, nous avons reçu des souris Rasa3+/- exprimant une protéine Rasa3 tronquée et catalytiquement inactive. Comme les souris Rasa3-/- meurent pendant la gestation, des transferts de cellules hématopoïétiques souches de foie fœtal d’embryons Rasa3-/- ont été réalisés dans des souris SCID. Les souris SCID après reconstitution développent le système hématopoïétique des souris Rasa3-/-.<p>Nous avons découvert que l’expression de Rasa3 est régulé au niveau de l’ARNm et de la protéique après activation des lymphocytes B par la voie du récepteur aux antigènes (BCR).<p>L’analyse des souris Rasa3 TgN a permis de mettre en évidence une diminution de la survie des lymphocytes B in vitro et une diminution de la réponse immune à un antigène T-indépendant (TI) in vivo. Les souris TgM présentent un phénotype inverse aux souris TgN.<p>Six à 8 semaines après reconstitution, les souris SCID Rasa3-/- présentent un phénotype opposé à celui des souris TgN :leurs lymphocytes B ont une meilleure survie in vitro et une meilleure réponse immune à un antigène TI in vivo. On observe également chez ces souris SCID Rasa3-/- une augmentation du nombre de lymphocytes B dans certaines sous-populations spléniques.<p>L’observation prolongée des souris SCID Rasa3-/- a mis en évidence une diminution de leur survie. A l’autopsie, 90% d’entre elles développent une splénomégalie reflétant une hématopoïèse extra-médullaire. Soixante pourcents d’entre-elles présentent de l’ostéosclérose dans de la cavité médullaire du fémur, associée à une augmentation du pourcentage de mégacaryocytes. D’un point de vue sanguin, les souris SCID Rasa3-/- développent une thrombocytopénie sévère. Des hémorragies et une anémie régénérative ont également été observées. Les causes exactes de la thrombocytopénie doivent encore être investiguées dans le cadre de ce travail.<p>Enfin, environ 15 % des souris SCID Rasa3-/- ont montré une infiltration massive de la rate et de la moelle osseuse par des cellules progénitrices CD117+, suggérant qu’une fraction d’entre-elles développent une leucémie myéloïde aigue.<p> / Doctorat en Sciences / info:eu-repo/semantics/nonPublished